Silverback Therapeutics nabs $78.5m Series B

Seattle-based Silverback Therapeutics, a biopharmaceutical company, has secured $78.5 million in Series B financing.

11 March 2020

Seattle-based Silverback Therapeutics, a biopharmaceutical company, has secured $78.5 million in Series B financing. U.S. Venture Partners led the round.

Source: Press Release

Register now

Get limited access to our industry news, analysis and data, plus regular email updates

Email address

First name

first name

Last name

last name

Organisation

Country Phone number Job title

Job Title

To register, please review and accept our terms and conditions and privacy notice. I accept: sourceRegistration

Not for publication, email or dissemination

Nearly there!

Share this:

Register now

Login

Sign in to your account

Nearly there!

We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case it’s been delivered there.